Brian Abrahams
Stock Analyst at RBC Capital
Total Price Targets
56
Stocks Covered
19
Sectors
Healthcare
Most Recent
Mar 2, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Brian Abrahams
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| AARD | Aardvark Therapeutics, Inc. Common Stock | $6.00 | $5.43 | +10.5% | 2 | Mar 2, 2026 |
| REGN | Regeneron Pharmaceuticals, Inc. | $765.00 | $703.72 | +8.7% | 10 | Mar 2, 2026 |
| KYMR | Kymera Therapeutics, Inc. | $108.00 | $81.54 | +32.5% | 2 | Feb 26, 2026 |
| PTCT | PTC Therapeutics, Inc. | $82.00 | $65.06 | +26.0% | 3 | Feb 20, 2026 |
| VRTX | Vertex Pharmaceuticals Incorporated | $546.00 | $425.06 | +28.5% | 7 | Jan 22, 2026 |
| CTNM | Contineum Therapeutics, Inc. Class A Common Stock | $22.00 | $13.38 | +64.4% | 2 | Nov 21, 2025 |
| KPTI | Karyopharm Therapeutics Inc. | $19.00 | $8.77 | +116.8% | 3 | Nov 4, 2025 |
| ATYR | aTyr Pharma, Inc. | $1.50 | $0.83 | +80.4% | 1 | Sep 15, 2025 |
| SION | Sionna Therapeutics, Inc. | $22.00 | $39.33 | -44.1% | 1 | Sep 3, 2025 |
| BIIB | Biogen Inc. | $213.00 | $186.69 | +14.1% | 4 | Jun 25, 2025 |
| GILD | Gilead Sciences, Inc. | $83.00 | $132.04 | -37.1% | 5 | Jan 7, 2025 |
| NMRA | Neumora Therapeutics, Inc. Common Stock | $4.00 | $2.53 | +58.1% | 4 | Jan 2, 2025 |
| NBIX | Neurocrine Biosciences, Inc. | $136.00 | $131.64 | +3.3% | 2 | Aug 29, 2024 |
| SRPT | Sarepta Therapeutics, Inc. | $181.00 | $21.60 | +738.0% | 5 | Aug 8, 2024 |
| INCY | Incyte Corporation | $66.00 | $96.41 | -31.5% | 1 | Jul 31, 2024 |
| CVS | CVS Health Corporation | $74.00 | $82.34 | -10.1% | 1 | Jun 28, 2024 |
| XENE | Xenon Pharmaceuticals Inc. | $55.00 | $56.81 | -3.2% | 1 | Jun 18, 2024 |
| DFTX | Definium Therapeutics, Inc. | $22.00 | $21.83 | +0.8% | 1 | Jun 5, 2024 |
| PLRX | Pliant Therapeutics, Inc. | $45.00 | $1.23 | +3573.5% | 1 | May 7, 2024 |
Recent Activity
- Mar 2, 2026— Set$765.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- Mar 2, 2026— Set$6.00price target onAARD(Aardvark Therapeutics, Inc. Common Stock)
- Feb 26, 2026— Set$108.00price target onKYMR(Kymera Therapeutics, Inc.)
- Feb 20, 2026— Set$82.00price target onPTCT(PTC Therapeutics, Inc.)
- Jan 27, 2026— Set$745.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- Jan 22, 2026— Set$546.00price target onVRTX(Vertex Pharmaceuticals Incorporated)
- Nov 21, 2025— Set$22.00price target onCTNM(Contineum Therapeutics, Inc. Class A Common Stock)
- Nov 14, 2025— Set$18.00price target onAARD(Aardvark Therapeutics, Inc. Common Stock)
- Nov 4, 2025— Set$19.00price target onKPTI(Karyopharm Therapeutics Inc.)
- Sep 16, 2025— Set$70.00price target onKYMR(Kymera Therapeutics, Inc.)
- Sep 15, 2025— Set$1.50price target onATYR(aTyr Pharma, Inc.)
- Sep 3, 2025— Set$22.00price target onSION(Sionna Therapeutics, Inc.)
- Jun 25, 2025— Set$213.00price target onBIIB(Biogen Inc.)
- Jun 17, 2025— Set$420.00price target onVRTX(Vertex Pharmaceuticals Incorporated)
- Jan 7, 2025— Set$58.00price target onPTCT(PTC Therapeutics, Inc.)
- Jan 7, 2025— Set$83.00price target onGILD(Gilead Sciences, Inc.)
- Jan 2, 2025— Set$4.00price target onNMRA(Neumora Therapeutics, Inc. Common Stock)
- Dec 19, 2024— Set$400.00price target onVRTX(Vertex Pharmaceuticals Incorporated)
- Nov 5, 2024— Set$451.00price target onVRTX(Vertex Pharmaceuticals Incorporated)
- Oct 9, 2024— Set$437.00price target onVRTX(Vertex Pharmaceuticals Incorporated)
Frequently Asked Questions
Who is Brian Abrahams?
Brian Abrahams is a stock analyst at RBC Capital covering 19 stocks primarily in Healthcare. They have issued 56 price targets since Mar 10, 2022.
What stocks does Brian Abrahams cover?
Brian Abrahams currently covers 19 stocks, including REGN, VRTX, GILD, SRPT, BIIB.
What is Brian Abrahams's latest price target?
Brian Abrahams's most recent price target was $765.00 on REGN (Regeneron Pharmaceuticals, Inc.), set on Mar 2, 2026.
What is Brian Abrahams's highest price target?
Brian Abrahams's highest issued price target is $1299.00 on REGN, set on Jun 13, 2024.
More Analysts at RBC Capital
Coverage based on publicly published price targets. Not investment advice.